

Lypro Biosciences to Present at Life Science Summit 2011

November 7, 2011

San Francisco, CA – Lypro Biosciences, Inc. (Lypro Bio) announced that Chief Executive Officer, Michelle S. Call, and Chief Scientific Officer, Robert O. Ryan, Ph.D., will present at the Life Science Summit on Thursday, November 17, 2011 at 1:15 p.m. in New York City. Life Science Summit is a transnational meeting focused on moving commercially relevant discoveries into the development process. The meeting is hosted by Stony Brook University in collaboration with Demy-Colton Life Science Advisors. It will be held November 16-17 at the Sentry Centers Midtown East in New York City, NY.

The Company will be introducing recent data demonstrating the ability to delivery drugs to specific cells through the use of its proprietary drug delivery technology, NanoDisk. "We are excited to present the findings from our recent studies which demonstrate the ability to target the delivery of drug to specific cells," said Dr. Ryan, Chief Scientific Officer of Lypro Biosciences. "We are hopeful our work will lead to a novel therapeutic for the treatment of mantle cell lymphoma."

"The fundamentals behind the targeted NanoDisk therapeutic for mantle cell lymphoma can be broadly applied to other cancers and other disease conditions where a specific cell receptor can be identified," said Michelle S. Call, President and CEO.

About Lypro Biosciences

Lypro Biosciences, Inc. is preclinical stage therapeutic company, located in the San Francisco Bay Area and financed by angel investors including Life Science Angels. Lypro Bio's proprietary nanotechnology drug delivery platform, NanoDisk, has applications across numerous disease indications. Its product pipeline includes therapies for infectious diseases such as aspergillosis and leishmaniasis, as well as for cancers such as mantle cell lymphoma.

Contacts:

Michelle S. Call President and CEO Lypro Biosciences, Inc. info@lyprobio.com www.lyprobio.com